Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group

Research Group ◽

Triple Negative ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Oncology Research ◽

Multicenter Phase ◽

Final results of weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group

Annals of Oncology ◽

10.1093/annonc/mdw365.21 ◽

2016 ◽

Vol 27 ◽

pp. vi74 ◽

Cited By ~ 1

Author(s):

M. Nikolaou ◽

E. Saloustros ◽

A. Polyzos ◽

C. Christophyllakis ◽

N. Kentepozidis ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Research Group ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Oncology Research ◽

Multicenter Phase ◽

P47 Capecitabine, oxaliplatin and bevacizumab as first line treatment for elderly patients with metastatic colorectal cancer: a multicenter phase II trial from Hellenic Oncology Research Group

Critical Reviews in Oncology/Hematology ◽

10.1016/s1040-8428(09)70085-x ◽

2009 ◽

Vol 72 (1) ◽

pp. S35 ◽

Cited By ~ 1

Author(s):

L. Vamvakas ◽

A. Prinari ◽

A. Karampeazis ◽

N. Androulakis ◽

S. Giassas ◽

...

Keyword(s):

Colorectal Cancer ◽

Elderly Patients ◽

Metastatic Colorectal Cancer ◽

Research Group ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Oncology Research ◽

Multicenter Phase ◽

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Clinical Breast Cancer ◽

10.1016/j.clbc.2018.12.008 ◽

2019 ◽

Vol 19 (2) ◽

pp. e283-e296 ◽

Cited By ~ 7

Author(s):

Lynn Symonds ◽

Hannah Linden ◽

Vijayakrishna Gadi ◽

Larissa Korde ◽

Eve Rodler ◽

...

Keyword(s):

Breast Cancer ◽

Targeted Therapy ◽

Phase Ii ◽

Targeted Therapies ◽

Triple Negative ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.01.065 ◽

2021 ◽

Author(s):

A. Brufsky ◽

S.B. Kim ◽

Ž. Zvirbule ◽

A. Eniu ◽

J. Mebis ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Primary Analysis ◽

Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study

Chemotherapy ◽

10.1159/000356156 ◽

2013 ◽

Vol 59 (3) ◽

pp. 207-213 ◽

Cited By ~ 4

Author(s):

Yuqian Liao ◽

Ying Fan ◽

Yiye Wan ◽

Jun Li ◽

Lixiang Peng

Keyword(s):

Breast Cancer ◽

Pilot Study ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Limited Efficacy ◽

SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz100.047 ◽

2019 ◽

Vol 30 ◽

pp. iii63

Author(s):

V. Boni ◽

C. Alemany ◽

J.L. Meisel ◽

R. Sinha ◽

D. Sterrenberg ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Ib ◽

Open Label Phase ◽

OT3-01-08: Phase II Study of S-1 Combined with Cisplatin in the First-Line Treatment of Triple Negative Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-08 ◽

2011 ◽

Author(s):

Y Fan ◽

BH Xu

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Abstract OT2-08-02: Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)

10.1158/1538-7445.sabcs19-ot2-08-02 ◽

2020 ◽

Cited By ~ 1

Author(s):

Peter Schmid ◽

Javier Cortes ◽

Mark Robson ◽

Hiroji Iwata ◽

Roberto Hegg ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

10.1158/1538-7445.sabcs19-pd1-06 ◽

2020 ◽

Cited By ~ 2

Author(s):

Hyo (Heather) Han ◽

Sami Diab ◽

Carlos Alemany ◽

Reva Basho ◽

Ursa Brown-Glaberman ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase 1B ◽

IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps1104 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS1104-TPS1104 ◽

Cited By ~ 8

Author(s):

Leisha A. Emens ◽

Sylvia Adams ◽

Sherene Loi ◽

Andreas Schneeweiss ◽

Hope S. Rugo ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Triple Negative ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽